LifeArc is a self-funded charitable medical research organisation. It takes science ideas out of the lab and helps turn them into medical breakthroughs that can be life-changing for patients. LifeArc has been doing this for more than 25 years and its work has contributed to five licensed medicines, including cancer drug pembrolizumab (Keytruda®), lecanemab for Alzheimer’s (Leqembi), and a diagnostic for antibiotic resistance.

LifeArc’s teams are experts in drug and diagnostics discovery, technology transfer, and intellectual property. Its work is in translational science – bridging the gap between academic research and clinical development, providing funding, research and expert knowledge, all with a clear and unwavering commitment to having a positive impact on patient lives. LifeArc is committed to spending £1.3 billion by 2030 in areas of high unmet medical need.